



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 24.08.2020

To,
The Manager,
Department of Corporate Relationship,
BSE Limited
25th P. J. Towers,
Dalal Street, Fort,
Mumbai – 400 001

Scrip Code: 524414

**Subject: Submission of Standalone Unaudited Financial Results in compliance
With Regulation 33 of SEBI (LODR) Regulations, 2015**

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the following:

- 1) Standalone Unaudited Financial Results of the Company for the Quarter ended on 30th June, 2020.
- 2) Limited Review Report on Standalone Unaudited Financial Results for the quarter ended on 30th June, 2020.

Kindly take the aforesaid information on your record and oblige.

Thanking you,

Yours truly,
For **Norris Medicines Limited**

(Vinay Rana)
Company Secretary

Encl: As above



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2020

Sr. No.	Particulars	(Rs. In Lakhs)			
		Quarter Ended			Year Ended
		30.06.2020 Unaudited	31.03.2020 Audited	30.06.2019 Unaudited	31.03.2020 Audited
i	Revenue from Operations	184.23	135.57	296.29	784.37
ii	Other Income	2.45	7.69	0.70	8.52
iii	Total Revenue (i+ii)	186.68	143.26	296.99	792.89
iv	Expenses				
	(a) Cost of Materials Consumed	89.65	174.01	153.66	516.30
	(b) Changes in Inventories of Finished Goods, work in Progress and stock in trade	3.98	-80.22	8.94	-63.90
	(c) Employee Benefit Expenses	48.50	72.93	82.77	322.54
	(d) Finance Costs	11.11	35.87	17.47	88.23
	(e) Depreciation and Amortisation Expense	18.00	19.48	17.80	72.88
	(f) Other expenditure	40.71	60.21	64.35	224.94
	Total Expenses (iv)	211.95	282.28	344.99	1160.99
v	Profit/ (Loss) before exceptional and extraordinary items and tax (iii-iv)	-25.27	-139.02	-48.00	-368.10
vi	Exceptional items	0.00	0.00	0.00	0.00
vii	Profit/ (Loss) before extraordinary items and tax (v-vi)	-25.27	-139.02	-48.00	-368.10
viii	Extraordinary items	0.00	0.00	0.00	0.00
ix	Profit/ (Loss) before Tax (vii-viii)	-25.27	-139.02	-48.00	-368.10
x	Tax Expense				
	(a) Current Tax	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	-83.99	0.00	-83.99
xi	Profit / Loss after Tax	-25.27	-55.03	-48.00	-284.11
xii	Other Comprehensive Income	0.00	0.00	0.00	0.00
	Total Comprehensive Income for the period	-25.27	-55.03	-48.00	-284.11
xiii	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58
xiv	- Basic and diluted	-0.25	-0.55	-0.48	-2.84

Notes:

- 1) The above Unaudited Financial Results have been reviewed by the Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors.
- 2) The Company is having one segment only and therefore Segmental Reporting is not applicable.
- 3) There are no exceptional/ extraordinary items during the quarter ended 30.6.2020.
- 4) Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures

For Norris Medicines Limited

Vimal D Shah
Managing Director

Date: 24.08.2020
Place: Ankleshwar



C-24, Ground Floor, Sardar Patel Municipal Market, Shaktinath, Bharuch - 392 001.
Tel. 02642-263302, Mobile : 98241 25540 E-mail : harishnjadav@yahoo.com

Date : 24th August, 2020

To
The Board of Directors
Norris Medicines Limited
Ankleshwar

Limited Review Report on Standalone Quarterly Unaudited Financial Results of Norris Medicines Limited to the Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015.

1. **INTRODUCTION**

We have reviewed the accompanying statement of Standalone unaudited financial results of **NORRIS MEDICINES LIMITED** ("the company") for the Quarter ended **30th June, 2020**, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019. This Statement is the responsibility of the Company's Management and has been approved by the Board of directors. Our responsibility is to issue a report on the Statement based on our review.

2. **SCOPE OF REVIEW**

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. **SCOPE OF REVIEW**

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards, i.e. Indian Accounting Standard ("Ind AS") and other recognized accounting practices and






C-24, Ground Floor, Sardar Patel Municipal Market, Shaktinath, Bharuch - 392 001.
Tel. 02642-263302, Mobile : 98241 25540 E-mail : harishnjadav@yahoo.com

policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bharuch
Date: 24/08/2020

C-24, Ground Floor,
Sardar Patel Municipal Market,
Shaktinath, Bharuch- 392001
Gujarat

For, H. N. JADAV & Co.
Chartered Accountants



CA HARISHCHANDRA JADAV

Proprietor

M. No. 040525

(Firm Reg. No. 103801W)

UDIN: 20040525AAAABO8624